Sienna has entered into an agreement with VivaZome to assist in the development of a commercial and scalable purification process for VivaZome’s exosome-based therapies. This will be the first potential therapeutic application of Sienna’s capture technology, EXO-NET. Sienna will provide EXO-NET beads which rapidly and specifically capture exosomes, potentially enabling the development of a commercial purification process for exosomes used in treatment therapies.

Read full media release here

Dr Haylock joined the Company as Chief Scientific Officer (CSO) in July, 2019. In his role as CEO, Dr Haylock will maintain his CSO function. Previously Dr Haylock has held senior leadership and management roles iat CSIRO, the Australian Stem Cell Centre, the Peter MacCallum Cancer Centre and the Institute for Medical and Veterinary Sciences. David has a wealth of experience in stem cell biology, cellular therapies and cell manufacturing, all directly relevant to VivaZome’s exosome therapies.

Read full media release here

Under the agreement, ToolGen will use its CRISPR/Cas9 technology to introduce gene edits into selected cell types to selectively altering the content and characteristics of exosomes produced by the cells.The agreement includes an option for VivaZome to license ToolGen’s technology, as well as any IP arising from the research program.

Read full media release here

VivaZome Therapeutics has been awarded an Australian Government CRC-P grant of $2.18m in support of the project “Enabling Exosome Therapy: Developing an Advanced Manufacturing Process”, with the funds provided under the Advanced Manufacturing Scheme. Joining VivaZome in the CRC-P are La Trobe University and SeerPharma Pty Ltd, each of which bring high-level scientific and operational skills to the 3 –year project. VivaZome will also engage with the CSIRO to provide expertise in industrial–scale manufacturing.

Read full media release here